Company: Gritstone bio, Inc.
Job title: President, Chief Executive Officer & Co-Founder
Taking Advantage of Tumour Neoantigen Vaccines – The Randomised Trial Wave is Breaking Soon 9:00 am
Understanding why tumour neoantigen vaccines have been studied extensively in single-arm studies, in combination with ICB, in patients with very advanced disease Showcasing how such studies in cold tumours (e.g., MSS-CRC) have disclosed molecular responses (MR) in 40-45% of subjects, with extended overall survival observed in MR+ vs MR- patients An exclusive look at how…Read more
day: Conference Day Two